NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

SONN

Sonnet BioTherapeutics Holdings Inc

Jul 03 • 04:00PM ET

3.92

Dollar change -0.23
Percentage change -5.54	%

Healthcare • Biotechnology • USA • NASD

Peers: AXSM BTAI DTIL CYCC CRIS MESO ADAP IMUX APRE GERN

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-12.83	Insider Own	1.22%	Shs Outstand	3.17M	Perf Week	240.87%
Market Cap	12.41M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.13M	Perf Month	235.88%
Enterprise Value	10.44M	PEG	-	EPS next Q	-0.49	Inst Own	5.09%	Short Float	1.94%	Perf Quarter	199.24%
Income	-13.29M	P/S	12.41	EPS this Y	69.52%	Inst Trans	74.16%	Short Ratio	0.03	Perf Half Y	164.86%
Sales	1.00M	P/B	18.49	EPS next Y	-	ROA	-272.65%	Short Interest	0.06M	Perf YTD	168.49%
Book/sh	0.21	P/C	6.02	EPS next 5Y	-	ROE	-714.96%	52W High	10.02 -60.88%	Perf Year	-47.31%
Cash/sh	0.65	P/FCF	-	EPS past 3/5Y	83.46% 85.27%	ROIC	-2006.15%	52W Low	1.08 262.96%	Perf 3Y	-99.42%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-66.23% -77.19%	Gross Margin	91.31%	Volatility	59.08% 18.48%	Perf 5Y	-99.96%
Dividend TTM	-	EV/Sales	10.44	EPS Y/Y TTM	69.65%	Oper. Margin	-1376.89%	ATR (14)	0.35	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	1.03	Sales Y/Y TTM	978.39%	Profit Margin	-1328.60%	RSI (14)	87.17	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.03	EPS Q/Q	-240.61%	SMA20	168.79%	Beta	0.76	Target Price	20.00
Payout	-	Debt/Eq	0.14	Sales Q/Q	-	SMA50	190.07%	Rel Volume	2.89	Prev Close	4.15
Employees	13	LT Debt/Eq	0.00	Earnings	May 20	SMA200	63.34%	Avg Volume	2.14M	Price	3.92
IPO	Jul 27, 2005	Option/Short	No / No	EPS/Sales Surpr.	0.00% -	Trades		Volume	6,186,473	Change	-5.54%

May-01-25 09:00AM	Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit (GlobeNewswire)
Apr-16-25 09:10AM	Sonnet Releases Virtual Investor 'What This Means' Segment (GlobeNewswire)
Apr-04-25 09:00AM	Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose (GlobeNewswire)
Apr-01-25 04:15PM	Sonnet Announces Release of Corporate Update Video (GlobeNewswire) -5.22%
07:30AM	Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. (GlobeNewswire)
09:05AM	Loading…
Mar-26-25 09:05AM	Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas (GlobeNewswire)
Mar-19-25 08:50AM	Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein (GlobeNewswire)
Mar-11-25 08:45AM	Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire)
Feb-26-25 09:00AM	Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors (GlobeNewswire)
Feb-19-25 08:35AM	Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates (GlobeNewswire)
Feb-18-25 09:15AM	Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference (GlobeNewswire)
Feb-13-25 08:30AM	Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer (GlobeNewswire)
08:00AM	Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update (GlobeNewswire)
Jan-28-25 09:05AM	Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB Platform Technology (GlobeNewswire)
Jan-22-25 08:35AM	Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar (GlobeNewswire) +29.87%
09:05AM	Loading…
Jan-21-25 09:05AM	Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas (GlobeNewswire)
Dec-23-24 09:20AM	Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment (GlobeNewswire) -7.69%
Dec-17-24 08:50AM	Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Dec-09-24 03:42PM	Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -5.71%
08:45AM	Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial (GlobeNewswire)
Dec-04-24 09:20AM	Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action (GlobeNewswire) -16.18%
Nov-12-24 09:15AM	Sonnet BioTherapeutics Releases Virtual Investor ' What this Means Segment (GlobeNewswire) -7.58%
Nov-06-24 01:20PM	Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -11.40%
08:30AM	Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates (GlobeNewswire)
Oct-17-24 08:45AM	Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq (GlobeNewswire) +20.28%
Oct-10-24 09:17AM	Sonnet BioTherapeutics Strategic Deal to Develop DPN Treatment (TipRanks)
Oct-09-24 08:45AM	Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India (GlobeNewswire)
Oct-04-24 08:30AM	Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs (GlobeNewswire)
Sep-30-24 09:00AM	Sonnet BioTherapeutics Announces Launch of CEO Corner Platform (GlobeNewswire) +17.85%
Sep-25-24 08:30AM	Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split (GlobeNewswire) -19.22%
08:30AM	Loading…
Sep-18-24 08:30AM	Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors (GlobeNewswire)
Sep-04-24 09:15AM	Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire) +10.60%
Aug-19-24 08:45AM	Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic Cancer (GlobeNewswire)
Aug-14-24 10:56PM	SONN Stock Earnings: Sonnet BioTherapeutics Beats EPS for Q3 2024 (InvestorPlace) +13.29%
08:35AM	Sonnet BioTherapeutics Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-24-24 03:00PM	Sonnet BioTherapeutics (NASDAQ:SONN) Participates in Virtual Investor 'What This Means' Segment Hosted by JTC Team (ACCESSWIRE)
08:30AM	Sonnet BioTherapeutics Reports Encouraging Data from Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) That Support Advancement into Phase 2 Study (GlobeNewswire)
Jun-20-24 08:30AM	Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds (GlobeNewswire) -32.03%
Jun-13-24 08:00AM	Sonnet BioTherapeutics Announces the Generation and Characterization of Two Novel Immunotherapeutic Pipeline Drug Candidates, SON-1411 and SON-1400, Each Containing a Variant IL-18 Domain (GlobeNewswire)
May-28-24 08:00AM	Sonnet BioTherapeutics to Present SB221 as a Trial in Progress at the ASCO 2024 Annual Meeting (GlobeNewswire)
May-22-24 07:00AM	Sonnet BioTherapeutics Announces Review of Strategic Alternatives (ACCESSWIRE) +5.45%
May-20-24 09:15AM	Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with an anti-PD-L1, along with an Increase in the Dose-Escalation Target (ACCESSWIRE) -5.43%
May-15-24 09:53AM	SONN Stock Earnings: Sonnet BioTherapeutics Misses EPS for Q2 2024 (InvestorPlace)
May-14-24 04:15PM	Sonnet BioTherapeutics Provides Fiscal Year 2024 Second Quarter and Year-to-Date Business and Earnings Update (ACCESSWIRE)
May-06-24 07:00AM	Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference (ACCESSWIRE)
May-03-24 09:00AM	Sonnet BioTherapeutics Announces Participation in the EF Hutton Annual Global Conference (Newsfile)
Mar-19-24 07:30AM	Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting (ACCESSWIRE)
Mar-11-24 07:30AM	Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective (ACCESSWIRE) +11.89%
Feb-29-24 04:05PM	Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers (ACCESSWIRE) +10.67% -8.12%
Feb-14-24 07:30AM	Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update (ACCESSWIRE)
Dec-21-23 08:00AM	Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy (ACCESSWIRE) +19.25%
Dec-14-23 04:15PM	Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update (ACCESSWIRE) -9.62%
Oct-31-23 07:30AM	Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview (ACCESSWIRE)
Oct-25-23 07:30AM	Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering (ACCESSWIRE) -28.73%
Oct-17-23 08:00AM	Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting (ACCESSWIRE)
Sep-20-23 07:30AM	Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology (ACCESSWIRE) -6.70%
Sep-19-23 08:30AM	Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance (ACCESSWIRE)
Aug-31-23 10:55AM	Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock Split (ACCESSWIRE) -28.34%
Aug-16-23 07:30AM	Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US (ACCESSWIRE) +16.17%
Aug-14-23 08:00AM	Sonnet BioTherapeutics Provides Fiscal Year 2023 Third Quarter Business and Earnings Update (ACCESSWIRE)
Jul-31-23 09:00AM	Sonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology Conference (ACCESSWIRE)
Jun-28-23 08:00AM	Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement (ACCESSWIRE) -21.47%
Jun-23-23 08:00AM	Sonnet BioTherapeutics Announces Presentations at the 2023 Cytokine-Based Drug Development Summit and Provides Preliminary Update on the SON-080 Study in Chemotherapy-Induced Peripheral Neuropathy (ACCESSWIRE)
Jun-20-23 08:00AM	Sonnet BioTherapeutics Announces Regulatory Approval for Initiation of a Clinical Trial of SON-1010 Combined with Atezolizumab (ACCESSWIRE) -19.24%
May-10-23 07:30AM	Sonnet BioTherapeutics Provides Fiscal Year 2023 Second Quarter and Year-to-Date Business and Earnings Update (ACCESSWIRE)
Apr-18-23 04:01PM	Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 at the 2023 American Association for Cancer Research (AACR) Annual Meeting (ACCESSWIRE) -7.85% -8.88%
Apr-17-23 08:00AM	Sonnet BioTherapeutics Announces Webcast to Discuss Clinical Data from the SB101 Study with SON-1010 Being Presented at the AACR 2023 Annual Meeting (ACCESSWIRE)
Mar-14-23 04:31PM	Sonnet BioTherapeutics to Present Clinical Data from the SB101 Study with SON-1010 at the AACR 2023 Annual Meeting (ACCESSWIRE) -7.64%
Feb-13-23 08:00AM	Sonnet BioTherapeutics Provides Fiscal Year 2023 First Quarter Business and Earnings Update (ACCESSWIRE)
Feb-08-23 08:00AM	Sonnet BioTherapeutics Announces Pricing of $15.0 Million Underwritten Public Offering (ACCESSWIRE) -9.24%
Feb-01-23 08:00AM	Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates (ACCESSWIRE) -6.09%
Jan-19-23 08:00AM	Sonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-1010 (ACCESSWIRE)
Jan-09-23 08:00AM	Sonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer (ACCESSWIRE)
Dec-15-22 04:05PM	Sonnet BioTherapeutics Provides Fiscal Year 2022 Business and Financial Update (ACCESSWIRE)
Nov-02-22 08:00AM	Sonnet BioTherapeutics Announces Interim Data in Two Phase 1 Dose-Escalation Trials of SON-1010 (ACCESSWIRE) -27.56%
Nov-01-22 04:05PM	Sonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Companys Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022 (ACCESSWIRE) +46.63%
Oct-31-22 07:30AM	Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates (ACCESSWIRE) +66.38%
Oct-04-22 08:00AM	Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (ACCESSWIRE) +8.78%
Sep-26-22 08:00AM	Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee (ACCESSWIRE) +16.15%
Sep-21-22 08:00AM	Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010 (ACCESSWIRE) -12.58%
Sep-16-22 08:30AM	Sonnet BioTherapeutics Announces 1-for-14 Reverse Stock Split (ACCESSWIRE) -14.10%
Aug-15-22 04:05PM	Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Business and Earnings Update (ACCESSWIRE) -9.70%
Jul-22-22 07:00AM	Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy (ACCESSWIRE)
Jul-21-22 07:30AM	Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers (ACCESSWIRE)
Jun-09-22 07:00AM	Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition (ACCESSWIRE) +23.00%
Jun-02-22 09:25AM	Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum (ACCESSWIRE)
May-10-22 08:15AM	Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update (ACCESSWIRE)
Apr-13-22 07:00AM	Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors (ACCESSWIRE) -14.50%
Apr-08-22 01:05PM	Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting (ACCESSWIRE)
Mar-16-22 07:00AM	Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors (ACCESSWIRE) +86.73%
Feb-09-22 06:30AM	Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting (ACCESSWIRE)
Feb-08-22 07:00AM	Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update (ACCESSWIRE)
Dec-20-21 12:58PM	We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate (Simply Wall St.)
Dec-17-21 06:30AM	Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update (ACCESSWIRE) -7.39%
Aug-30-21 04:01PM	Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410) (ACCESSWIRE) +23.43%
Aug-19-21 09:35PM	Sonnet BioTherapeutics Announces Pricing of $30 Million Underwritten Public Offering (ACCESSWIRE) +63.74% -48.25%
Aug-16-21 06:30AM	Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update (ACCESSWIRE) -9.96%
Jun-14-21 07:45AM	Sonnet BioTherapeutics Announces Change in Date of Annual Meeting (ACCESSWIRE)
Jun-08-21 04:30PM	Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology (ACCESSWIRE)
May-17-21 07:00AM	Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update (ACCESSWIRE)

Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SONN

Sonnet BioTherapeutics Holdings Inc

Upgrade your FINVIZ experience